Compared to the placebo, there was a 22% reduced risk of developing acute kidney injury with SGLT2 inhibitors yet did not reach statistical significance (RR: 0.78, 95% CI: 0.54–1.14, p = 0.2 I2 = 0%) (Figure 8). The gene discussed is SLC5A2; the disease is acute kidney injury.